Kyowa Hakko Kirin Co., Ltd. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 2/14/2026)
| Balance Sheet | Total Assets | 1,107,860,000,000.00 | ROE | 80.64 % |
| Balance Sheet | Total Equity | 893,332,000,000.00 | ROA | 6.05 % |
| Cashflow | Capital Expenditures | -41,112,000,000.00 | P/FCF | 20.04 |
| Cashflow | Free Cash Flow | 58,904,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 100,016,000,000.00 | P/CF | 11.80 |
| Income | Earnings per Share (diluted) | 128.07 | Div. Yield | 2.75 % |
| Income | Net Income | 67,040,000,000.00 | P/E | 17.61 |
| Income | Shares Outstanding | 523,452,000.00 | P/B | 1.32 |
| Income | Total Revenue | 515,582,859,890.58 | P/S | 2.38 |
Ratios calculated on: 10/14/2026
Company Description
Kyowa Hakko Kirin Co., Ltd. is mainly engaged in medical product and Biochemical businesses. The Medical Product segment is engaged in the manufacture, sale and sales promotion of ethical drug and reagent for clinical test, the development of candidate substances for new drugs, as well as the research and development of technologies for antibody drug creation, among others. It also involved in the contracting, retail and wholesale, and insurance agency businesses. The Biochemical segment manufactures and sells medical and industrial materials, mainly amino and nucleic acids, and healthcare products. This segment also designs and constructs facilities. As of December 31, 2013, it had 47 subsidiaries, three associated companies and one parent company.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.kyowa-kirin.co.jp
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more